Latest News
Digital Twinning, and how EdgeTI (CTRL.V) is a serious story you’ve never heard of
Bionxt Solutions (BNXT.C): Seeking to confirm national-level cancer drug patent
Why Prospera Energy (PEI.V) might be a transformational investment opportunity in Canadian oil & gas
Sparc AI (SPAI.C) completes development of drone advanced target acquisition system
Plurilock (PLUR.V) lands $19 million deal, largest in their history
Rex Resources (OWN.V) continues gearing up with BC gold property
Medexus Pharmaceuticals’ (MDP.T) financials are coming!
On February 8th, Medexus Pharmaceuticals, a Canadian-based specialty pharma company, will release its quarterly financials. Why is this a big deal? Well, the company, serving both Canada and the US, is selling more than its market value. How crazy is that?
In this episode of Investor’s Roundtable, the crew at Equity Guru dig in Medexus and lay out its revenue model and how there is a complete disconnect between market valuation and the business the company is currently doing, never mind the growth potential and possible portfolio additions. Should you be putting Medexus on your investment radar? Tune in and find out for yourself.
Enjoy!
Related Posts
Potential of Medexus Pharmaceuticals: Chris Parry gets into what investors are missing
Medexus Pharma (MDP.TO) Breaks Records: A Deep Dive into Quarterly Earnings, Portfolio Growth, and Future Opportunities
Medexus Pharmaceuticals (MDP): A Roller Coaster Ride to Success
Medexus Pharmaceuticals Sets New Revenue Records and Continues Expansion with Innovative Products and Financing
Medexus Pharmaceuticals (MDP.T) deals with its debentures
Medexus CEO (MDP.T) on creating Canada’s specialty pharma success story
More on MDP.T
Medexus Pharma (MDP.T) – Investor Roundtable Video #3
Medexus Pharma (MDP.T) – Three Minute Hits Video
Medexus Pharmaceuticals (MDP.T) – First Glance with Jody Vance E102
Biotech Sector Roundup – Investor Roundtable Video
Medexus Pharma’s (MDP.T) specialty pharma investment value on the rise